Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results
Closing of the €115 million licensing transaction with SERB Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026 The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase) LUND, Sweden, Nov. 11,...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.